Measles, mumps, rubella and varicella virus vaccine live - Biologic Drug Details

Summary for measles, mumps, rubella and varicella virus vaccine live

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for measles, mumps, rubella and varicella virus vaccine live

Recent Clinical Trials for measles, mumps, rubella and varicella virus vaccine live

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Kyverna Therapeutics	PHASE1
Bruce Cree	PHASE1

See all measles, mumps, rubella and varicella virus vaccine live clinical trials

Pharmacology for measles, mumps, rubella and varicella virus vaccine live

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Herpes Zoster Virus Vaccine Live Attenuated Measles Virus Vaccine Live Attenuated Mumps Virus Vaccine Live Attenuated Rubella Virus Vaccine Live Attenuated Varicella Zoster Virus Vaccine
Chemical Structure	Chickenpox Vaccine Herpes Zoster Vaccine Measles Vaccine Mumps Vaccine Rubella Vaccine Vaccines, Attenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for measles, mumps, rubella and varicella virus vaccine live Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for measles, mumps, rubella and varicella virus vaccine live Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	PROQUAD	measles, mumps, rubella and varicella virus vaccine live	For Injection	125108		2038-03-15	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PROQUAD	measles, mumps, rubella and varicella virus vaccine live	For Injection	125108		2041-04-30	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PROQUAD	measles, mumps, rubella and varicella virus vaccine live	For Injection	125108		2017-12-18	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for measles, mumps, rubella and varicella virus vaccine live Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for measles, mumps, rubella and varicella virus vaccine live

Country	Patent Number	Estimated Expiration
Argentina	080111
China	102740879
Hong Kong	1173657

Measles, Mumps, Rubella and Varicella Virus Vaccine Live: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is the product and how does demand behave across geographies?

Measles, mumps, rubella and varicella virus vaccine live (commonly the combined “MMRV” vaccine) sits at the center of routine childhood immunization schedules and outbreak response policies where varicella vaccination is mandated or strongly incentivized. Demand is driven by:

• Birth cohort size (primary volume driver)
• National immunization schedule adherence (dose uptake and catch-up)
• Vaccine procurement mechanics (tender cycles, multi-year contracting, contract splitting between suppliers)
• Substitution effects between combination products (MMRV vs separate MMR and varicella components) where health systems retain formularies and procurement leverage

Across markets, uptake is typically highest in countries with long-running childhood vaccination programs and stable cold-chain procurement. In lower-coverage settings, demand is most sensitive to funding cycles and immunization campaign timing.

Who sets the competitive and price floor?

The market is shaped by branded biologics with distinct label claims and tender eligibility. In practice, competitive dynamics follow procurement patterns:

• Public-sector tenders often standardize to a small set of eligible products, using price and supply reliability as primary selection criteria.
• Private-sector purchase in certain regions can sustain higher net pricing but still faces payer pressure tied to routine schedule compliance and bundled childhood vaccines.

MMRV competes against two broad approaches:

1. Single-antigen varicella + MMR combination as separate shots (often chosen where health systems prefer component-level procurement)
2. Other combination vaccines where national schedules and provider practices influence utilization

The key commercial determinant is whether regulators and payers support MMRV as preferred over separate components in the target pediatric age bands.

What do regulators require and how does that affect supply stability?

MMRV is a live attenuated vaccine and requires manufacturing that is sensitive to process controls and lot release. Commercial supply stability tends to be constrained by:

• Manufacturing capacity and lot release complexity (multiple antigens in a single formulation)
• Quality systems and deviations that can trigger batch holds or slower supply ramps
• Cold-chain handling and distribution discipline tied to routine pediatric delivery

Where tendering governments rely on guaranteed delivery windows, any supply disruption can shift volumes to alternative products in the next procurement cycle, resetting market share even if the original product regains supply later.

What is the financial trajectory signal from recent contract and market behavior?

Financial performance for MMRV is typically a blend of:

• Volume growth tied to schedule expansion and catch-up campaigns
• Price and mix effects from procurement outcomes
• Share shifts caused by switching between MMRV and separate MMR plus varicella dosing

MMRV-specific financial outcomes track broader childhood immunization spending trends, with two recurrent patterns seen in vaccine markets:

• Stable baseline demand in routine immunization geographies
• Discrete procurement-driven spikes aligned to tender awards and multi-year commitments

In markets with expanding varicella vaccination policy or higher coverage targets, the vaccine generally benefits from both new cohort penetration and catch-up initiatives. In markets with constrained budgets or preference for separate components, pricing pressure increases and utilization may lag.

How does public procurement influence net revenue and margins?

Vaccine net revenue is heavily influenced by tender design:

• Competitive bidding compresses net price versus list price.
• National procurement centralization makes revenue less dependent on physician-by-physician selling and more dependent on tenders and distribution partners.
• Contract structures (framework agreements, allocation caps, delivery schedules) can create quarter-to-quarter variability in recognized revenue, even when annual demand is stable.

For live pediatric biologics, margin stability is also influenced by:

• Manufacturing utilization (fixed-cost absorption across lots)
• Yield and release rates (quality system throughput)
• Supply contingency costs when distribution lead times extend during ramp periods

What does the product’s positioning imply for lifecycle risk?

MMRV faces lifecycle dynamics common to routine childhood vaccines:

• Near-term demand stability due to entrenched schedule use
• Medium-term risk from formulary preference for separate components, where local practice and procurement strategy can swing share
• Regulatory or guideline revisions that change age-group recommendations or dose schedules can shift utilization patterns without changing total immunization budgets

Because demand is schedule-driven, lifecycle “growth” tends to come from policy adoption and coverage expansion rather than major clinical adoption cycles.

Where does growth come from: policy shifts vs cohort expansion?

Two growth vectors dominate:

1. Policy and schedule changes
   • Addition of varicella vaccination to routine childhood schedules in countries that already use MMR
   • Changes that prefer combination products for program simplicity
2. Coverage expansion and catch-up
   • Higher first-dose and second-dose uptake
   • Campaign-driven catch-up in target age bands

Cohort expansion (birth-rate increases) plays a smaller role over short horizons than procurement and policy adoption.

What is the likely financial impact of substitution between MMRV and separate dosing?

Substitution matters because it changes both:

• Unit demand (combination vs separate components)
• Procurement complexity (one product vs two products)

When health systems compare clinical and operational factors, MMRV can lose share if separate products align better with existing procurement contracts or supply availability. Conversely, MMRV gains share when policymakers value program simplification and ensure consistent supply.

What are the core commercial constraints that shape financial outcomes?

MMRV’s commercial ceiling in any region is constrained by:

• Procurement eligibility and tender cycles
• Supply reliability under cold-chain requirements
• Switching costs at the provider level (stocks, clinic workflows, ordering patterns)
• Payer and policy preference for combination versus components

Financial trajectory therefore tends to move in step with procurement rhythms and guideline alignment rather than with unpredictable demand surges.

How does product labeling and regulatory status affect contracting?

Labeling governs:

• Approved age windows
• Dosing schedules
• Comorbidity and contraindication framing
• Catch-up guidance

Tender contracts and payer reimbursement often mirror label indications. If guidance tightens or expands eligible populations, commercial outcomes shift through contract terms and utilization protocols.

What should investors model for revenue over the next procurement cycles?

A practical modeling approach for MMRV centers on:

• Tender-based volume (award timing and allocation)
• Net price realization (competitive bids and mix)
• Share movement (MMRV vs separate MMR and varicella)
• Supply continuity (risk of delivery slippage)

The directionality is usually clear:

• When countries expand varicella coverage or prefer combination delivery, net revenue improves through higher unit volume and reduced substitution.
• When budgets tighten or health systems standardize on separate components, net revenue declines through lower price realization and/or utilization loss.

Key Takeaways

• MMRV demand is schedule-driven and moves primarily with birth cohorts, coverage, and policy adoption rather than discretionary purchasing.
• Public procurement sets the net price floor; quarterly revenue recognition often tracks tender awards and allocation schedules.
• Share is vulnerable to substitution between MMRV and separate MMR plus varicella dosing based on local procurement leverage and provider workflow.
• Manufacturing and lot release stability are decisive for revenue predictability because supply disruptions can shift volumes in the next tender cycle.
• Financial trajectory is most sensitive to guideline alignment and varicella program expansion, which increases eligible utilization and reduces substitution.

FAQs

Is MMRV mainly a routine immunization product or an outbreak product?

It is primarily a routine childhood immunization product, with outbreak-related uptake governed by national public health strategies and catch-up campaign execution timelines.

What drives unit volume for MMRV most consistently?

Birth cohort size plus schedule adherence (dose uptake) and catch-up coverage drive the most consistent unit volume in routine immunization markets.

What is the main lever that changes MMRV net revenue?

Net price realization from competitive public procurement and contract structure (tender outcomes, allocation, delivery schedules) typically dominates net revenue changes.

Why can MMRV lose share even if varicella vaccination grows?

Varicella program growth does not guarantee combination product capture. Health systems may prefer separate MMR and varicella components due to procurement contracts, existing supply, or operational constraints.

What operational factor most affects forecasting accuracy?

Supply continuity (manufacturing capacity, lot release timing, and cold-chain distribution execution) is the main operational driver of quarter-to-quarter volatility.

---

References

[1] U.S. Food and Drug Administration. “VARIVAX (varicella virus vaccine live) / ProQuad (measles, mumps, rubella and varicella virus vaccine live).” FDA product label and prescribing information. (Accessed via FDA labeling database.)
[2] World Health Organization. “Measles vaccines: position paper” and related immunization policy guidance. WHO.
[3] Centers for Disease Control and Prevention (CDC). “Measles, Mumps, and Rubella (MMR) Vaccine and Varicella (Chickenpox) Vaccine Guidance” and immunization schedule resources. CDC.